WO2008079838A1 - Compounds and uses thereof - Google Patents

Compounds and uses thereof Download PDF

Info

Publication number
WO2008079838A1
WO2008079838A1 PCT/US2007/088036 US2007088036W WO2008079838A1 WO 2008079838 A1 WO2008079838 A1 WO 2008079838A1 US 2007088036 W US2007088036 W US 2007088036W WO 2008079838 A1 WO2008079838 A1 WO 2008079838A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
arylalkyl
aryl
heterocycloalkyl
haloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/088036
Other languages
English (en)
French (fr)
Inventor
Peter Bernstein
James B. Campbell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to JP2009543160A priority Critical patent/JP2010514682A/ja
Priority to EP07855245A priority patent/EP2120563A4/en
Priority to US12/520,133 priority patent/US20100093699A1/en
Publication of WO2008079838A1 publication Critical patent/WO2008079838A1/en
Anticipated expiration legal-status Critical
Priority to US12/726,619 priority patent/US8389510B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention further provides a compound of the invention for use in the manufacture of a medicament for the treatment of a symptom or condition provided herein.
  • alkenyl refers to an alkyl group having one or more double carbon-carbon bonds. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, cyclohexenyl, and the like.
  • alkenylenyl refers to a divalent linking alkenyl group.
  • Esters can be formed between hydroxyl or carboxylic acid groups present in the compound and an appropriate carboxylic acid or alcohol reaction partner, using techniques well known in the art.
  • Procedure There are two components in the procedure: 1) unsuppressed responding components (unpunished) with 2 minutes in duration and 2) suppressed responding components (punished) with 3 minutes in duration.
  • unpunished components the houselights and both stimulus lamps over the response levers are turned on, the lever on the left-hand side of the chamber extends, and a food pellet is delivered following an average of 17 responses on the lever in the chamber (range 3 to 40 responses) - a variable ratio 17 schedule (VRl 7).
  • the punished components follow unpunished components, and during these, the right-hand lever is extended into the chamber, and the stimulus lamps and houselights are turned on and off at 1 s intervals, in succession, which serve as a cue for this component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2007/088036 2005-11-18 2007-12-19 Compounds and uses thereof Ceased WO2008079838A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009543160A JP2010514682A (ja) 2006-12-20 2007-12-19 化合物及びその使用
EP07855245A EP2120563A4 (en) 2006-12-20 2007-12-19 CONNECTIONS AND ITS USES
US12/520,133 US20100093699A1 (en) 2006-12-20 2007-12-19 Compounds and uses thereof - 177
US12/726,619 US8389510B2 (en) 2005-11-18 2010-03-18 Crystalline forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87096406P 2006-12-20 2006-12-20
US60/870,964 2006-12-20

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/057808 Continuation-In-Part WO2008116144A1 (en) 2005-11-18 2008-03-21 Methods of treating mood disorders
US53171709A Continuation-In-Part 2005-11-18 2009-09-17

Related Child Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2006/061072 Continuation-In-Part WO2007062339A2 (en) 2005-11-18 2006-11-18 Liquid formulations
US12/520,133 A-371-Of-International US20100093699A1 (en) 2006-12-20 2007-12-19 Compounds and uses thereof - 177
US9395708A Continuation-In-Part 2005-11-18 2008-11-07
US12/726,619 Continuation-In-Part US8389510B2 (en) 2005-11-18 2010-03-18 Crystalline forms

Publications (1)

Publication Number Publication Date
WO2008079838A1 true WO2008079838A1 (en) 2008-07-03

Family

ID=39562910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/088036 Ceased WO2008079838A1 (en) 2005-11-18 2007-12-19 Compounds and uses thereof

Country Status (5)

Country Link
US (1) US20100093699A1 (enExample)
EP (1) EP2120563A4 (enExample)
JP (1) JP2010514682A (enExample)
CN (1) CN101616585A (enExample)
WO (1) WO2008079838A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8071804B2 (en) 2007-10-24 2011-12-06 Dow Agrosciences Llc Process for the manufacture of R-(+)-2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propionic acid esters
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110878048B (zh) * 2018-09-06 2023-03-17 中国科学院上海药物研究所 作为防治精神障碍疾病的苯胺类化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
US7071331B2 (en) * 2003-02-22 2006-07-04 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
JPH0565257A (ja) * 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
DE602004028739D1 (de) * 2003-07-02 2010-09-30 Astrazeneca Ab Metabolit von quetiapine
US20060063754A1 (en) * 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
US20070105836A1 (en) * 2005-10-31 2007-05-10 Lars Pettersson Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4547505A (en) * 1983-03-25 1985-10-15 Degussa Aktiengesellschaft N-Phenyl-N-'-cycloalkylalkanoylpiperazine useful as analgetics and process for its production
US7071331B2 (en) * 2003-02-22 2006-07-04 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2120563A4 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071804B2 (en) 2007-10-24 2011-12-06 Dow Agrosciences Llc Process for the manufacture of R-(+)-2-(4-(4-cyano-2-fluorophenoxy)phenoxy)propionic acid esters
WO2009151393A1 (en) * 2008-06-14 2009-12-17 Astrazeneca Ab Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
US8715699B2 (en) 2009-12-31 2014-05-06 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US10010615B2 (en) 2009-12-31 2018-07-03 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US9597403B2 (en) 2009-12-31 2017-03-21 Kempharm, Inc. Amino acid conjugates of quetiapine, process for making and using the same
US9889198B2 (en) 2010-03-11 2018-02-13 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US8900604B2 (en) 2010-03-11 2014-12-02 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
US9511149B2 (en) 2010-03-11 2016-12-06 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
EP2544536A4 (en) * 2010-03-11 2013-08-14 Kempharm Inc Fatty Acid Conjugates Of Quetiapine And Methods Of Making And Using It
US9890150B2 (en) 2010-03-11 2018-02-13 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
EP3476218A1 (en) * 2010-03-11 2019-05-01 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Also Published As

Publication number Publication date
EP2120563A4 (en) 2011-04-27
CN101616585A (zh) 2009-12-30
EP2120563A1 (en) 2009-11-25
JP2010514682A (ja) 2010-05-06
US20100093699A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
US20100016283A1 (en) Compounds and uses thereof - 150
JP3048067B2 (ja) 新規方法
US20100093699A1 (en) Compounds and uses thereof - 177
WO1993016055A1 (en) Hypolipidaemic benzothiazepine compounds
NZ290911A (en) 1,4-benzothiazepine 1,1-dioxides, preparative method and hypolipidemic medicaments
US8653257B2 (en) Dibenzothiazepine derivatives and uses thereof—424
US20100016284A1 (en) Compounds and uses thereof - 151
WO2008155573A1 (en) Cinnoline compounds for use in the treatment of schizophrenia
US20100056492A1 (en) Compounds and uses thereof - 152
WO2009151393A1 (en) Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [l,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
WO2009151392A1 (en) Novel derivatives of 11-piperazin-l-yldibenzo [b,f] [1,4] thiazepine for treating at least one syndrome or condition associated with schizophrenia and other psychotic disorders
SU1047389A3 (ru) Способ получени серусодержащих производных изохинолина
AU2012251921B2 (en) Dibenzothiazepine derivatives and use thereof
WO2011075470A1 (en) Quaternary piperidine compounds and uses thereof
DameWood Jr., Wilmington, DE (US); Ashokkumar 1 lilékkgppa sa ‘jnvli W11E1I {% t.? n’. DE GB 1164360 9/1969
JPH01110679A (ja) １，５−ベンゾチアゼピン誘導体

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780051537.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07855245

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 3679/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007855245

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009543160

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12520133

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE